Human Vaccines Market Size, Share & Trends Analysis Report By Type (Combination, Attenuated, Inactivated, Conjugate, Recombinant, Others) By Product (Rotavirus, Hepatitis, Influenza, Typhoid, Rubella, Others) By Distribution Channel (Hospital, Drugstores, Others) Based on Region, And Segment Forecasts, 2021 - 2027

  • Report ID: BMRC 1783 | Number of pages: 190 | Published Date: Dec 2021

    Published | Category: Vaccines | Delivery Timeline: 48 hrs

COVID-19
To know the impact of COVID-19 On Human Vaccines Market Size, Share & Trends Analysis Report By Type (Combination, Attenuated, Inactivated, Conjugate, Recombinant, Others) By Product (Rotavirus, Hepatitis, Influenza, Typhoid, Rubella, Others) By Distribution Channel (Hospital, Drugstores, Others) Based on Region, And Segment Forecasts, 2021 - 2027 Market

Request Now
Market Size Forecast Scenarios (Optimistic, Baseline and Pessimistic) 2021-2027

Global Human Vaccines Market was worth of USD 35.42 Billion in 2017 and it is expected to reach USD 83.54 Billion by the end of 2027 with the CAGR of 9.32% during the Forecast Period.

Global Human Vaccines Market: Global Size, Trends, Competitive, Historical & Forecast Analysis To 2021-2027,Increasing demand for various vaccines in developing countries, rising investment by key players, and government initiative in the vaccine development for different diseases are anticipated to drive the growth of Global human vaccines market

Scope of Global Human Vaccines Market Report-

Vaccine is a biological preparation that gives active acquired immunity for a particular infection. Vaccine contains an agent that resembles a disease-causing microorganism which is made up of dead or killed form of microbe or its surface protein. The agent boosts our immune system to recognize the agent that destroy the threat of the organism that enter in human body in future as well. Vaccine can be therapeutic or prophylactic; in fact, some vaccine provides complete immunity against infection for future.

Vaccination is the most effective method to prevent from an infectious disease and can also eradicate or restrict some of the disease. Smallpox is already eradicated and some of the diseases are almost restricted globally like measles, polio, and tetanus. The term vaccine or vaccination is derived from the variolae vaccinae by Edward Jenner. In 1879, Louis Pasteur created his first live vaccine on bacterial vaccine i.e., Chicken- Cholera. Furthermore the first used vaccine on human was created on rabies in 1885 including the development on typhoid and cholera vaccine in 1896.

COVID-19 pandemic has shown a mixed impact on the global human vaccine market, due to the factors such as shortage of the raw material & supply chain disruption which in turn hampered the production & supply due to the unavailability of transport & labor. Many players started vaccine manufacturing and increase in R&D activities for coronavirus vaccine which in turn hamper the vaccine production for other diseases.

Global Human Vaccines Market Segmentation: -

Global human vaccines market is segmented based on type, product, distribution channel, and region and country level. Based on the type the global human vaccines market is classified into combination, attenuated, inactivated, conjugate, recombinant and others. Based on the product the global human vaccines market is classified into rotavirus, hepatitis, influenza, typhoid, rubella and others. Based on the distribution channel the global human vaccines market is classified into hospital, drug stores and others.

By Type:

  • Combination
  • Attenuated
  • Inactivated
  • Conjugate
  • Recombinant
  • Others

By Product:

  • Rotavirus
  • Hepatitis
  • Influenza
  • Typhoid
  • Rubella
  • Others

By Distribution Channel:

  • Hospital
  • Drugstores
  • Others

 

Human Vaccines

Human Vaccines Manufacturers

Some major key players for global human vaccines market report cover prominent players like

  • Novartis AG,
  • Johnson & Johnson,
  • GlaxoSmithKline,
  • Pfizer Inc.,
  • AstraZeneca plc,
  • Bharat Biotech,
  • Takeda Pharmaceutical Company Ltd,
  • others

News:Biontech and Pfizer announced a vaccine candidate against Covid-19.

November 9th, 2020: A vaccine candidate against Covid-19 announced by the Biontech and Pfizer and was successful in first interim analysis. The vaccine candidate was found to be more accurate with 90% efficiency in Covid-19 without any evidence of SARS- CoV-2 infection. This is the mRNA based vaccine candidate BNT162b2 against SARS- CoV-2. This is the critical milestone in the development program when most of the infection is creating new record in hospitals worldwide. The first interim analysis was done on 62 cases where it reached the count nearly about 94 cases. The protection is achieved after 28 days after both the vaccination is done. Pfizer is one of the world leading innovative biopharmaceutical companies who collaborate with the hospitals, government and local to expand their service with affordable cost, reliable access world-wide. Biopharmaceutical New Technologies is next generation Immunotherapy Company for cancers and other serious disease. They are mainly exploits therapeutic drugs platforms and computational discovery.

Increasing demand for various vaccines in developing countries along with high prevalence of several diseases drives the global human vaccines market. The initiative taken by government and international bodies like world health organization, or Melinda gates foundation is also boosting the market. Developing countries are mainly focused on development of new vaccine or even schedule a national immunization program. According to the UNICEF, it supplies vaccine to reach 45 % of the children under the age of 5 years globally. UNICEF also works in 100 countries along with the NGO, UN agencies, and private sectors. According to WHO, in the year 2018, around 1, 40,000 deaths occurred due to measles globally, where most of them were under the age of 5 years. The vaccination program helped to lower the death rate of measles which dropped by 73%. Almost 86% of children received at least 1 dose of measles by the end of 2018.

Another factor that drives the global human vaccines market is investment done by government or healthcare institution or the key players towards new vaccine and its technologies. UNICEF and its healthcare partners invest in new technologies including the solar technology, and digital platform to reach most corners of the world.  According to the UNICEF, Melinda gates foundation, Swedish international development agency and UNICEF together announced 150 million dollar investment to support vaccine & health supplies in middle & low income countries. This investment will also help in sustaining national immunization program which will further lead to the lifesaving to many people in world. Furthermore, Melinda gates foundation has also made available the finance of 2.5 billion dollar.

However, factors that restrain the global human vaccines market from growth is the stringent regulatory policies for development of new vaccine including its R&D, and dropping profit in vaccine manufacturing will also contribute to hampering the human vaccine market. Additionally, opportunities in human vaccines market will rise when new development or investment will be initiated by the key players or governments along with innovation of new technologies for vaccine manufacturing.

North America is set to maintain its Dominance in Global Human Vaccines Market

North America is holding the highest market share in global human vaccines market, due to the increase in development and investment of vaccine by key players, including the immunization program for prevention of infectious diseases. According to WHO, the global vaccine action plan, a product of DoV Collaboration which was endorsed by the 194 members of states of world health assembly. This collaboration was led by WHO, UNICEF, Gavi the vaccine alliance, and USNIAID and BMGF. The main Moto of this plan was to prevent millions of death, which also recommended almost 15 strategies for implementation, development and content for the next decade. According to science direct, out of 194 almost 168 countries have implemented rubella vaccine and as of now only 10 people in U.S. have rubella infection each year.

Another factor that drives the global human vaccines market is the development and investment made by the key players in United States. U.S. has been more successful in research and development on the vaccine with most of the new vaccine were approved worldwide were developed by United States. Approximately 15 new vaccines were approved in the U.S between the years 1995-2014. Wyeth a subsidiary of Pfizer introduced a polyvalent pneumococcal conjugate vaccine for infants has used globally.

Asia Pacific is expected to be the fastest growing region in global human vaccines market owing to increasing awareness and prevalence of diseases among people, followed by increasing investments. Additionally, rising population along with increasing R&D activities followed by the breakout of various new diseases such as COVID is also likely to motivate market players for the development of innovative vaccines. The alternate approaches in advanced clinical development which includes injectable next gen rotavirus vaccine.  According to World Health Organization, the infection caused by rotavirus was approximately led to death of 5, 27,000 in developing countries. According to NCBI, around 40.78% of all diarrheal disease in children is infected by rotavirus in Southeast Asia.

Another factor that boosts the global human vaccines market is the investment done on manufacturing or development of the vaccine. Asian manufactures have developed low cost vaccines production solutions for the oral polio, diphtheria-tetanus-pertussis (DTP), and hepatitis B. According to World Health Organization, the death caused by hepatitis B is around 8, 20,000 in 2019 and 1.5 million new infection add each year.  China with largest population in Asia pacific spends more in research and development that boost the human vaccine market. According to the spacedirect.org, more than 369 dollar is spent on research and development followed by Japan with 166 dollar and India with 48 dollar etc.

The regions covered in this global human vaccines market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Sweden
  • Netherland
  • Turkey
  • Switzerland
  • Belgium
  • Rest of Europe

Asia-Pacific

  • South Korea
  • Japan
  • China
  • India
  • Australia
  • Philippines
  • Singapore
  • Malaysia
  • Thailand
  • Indonesia
  • Rest Of APAC

Latin America

  • Mexico
  • Colombia
  • Brazil
  • Argentina
  • Peru
  • Rest of South America

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest Of MEA
Report Analysis Details
Historical data 2015 - 2020
Forecast Period 2021 - 2027
Market Size in 2020: USD 35.42 Billion 
Base year considered 2020
Forecast Period CAGR %:

9.32% 

Market Size Expected in 2027: USD 83.54 Billion 
Tables, Charts & Figures: 175
Pages 200
Human Vaccines Manufacturers Novartis AG, Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., AstraZeneca plc, Bharat Biotech, Takeda Pharmaceutical Company Ltd, others
Segments Covered By Type, By Product, By Distribution Channel
Regional Analysis North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Key Benefits for Global Human Vaccines Report–

  • Global Human Vaccines report covers in-depth historical and forecast analysis.
  • Global Human Vaccines research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Human Vaccine Manufacturers, Competitive Analysis, Regional and Country Level.
  • Global Human Vaccines report helps to identify opportunities in the marketplace.
  • Global Human Vaccines report covers an extensive analysis of emerging trends and competitive landscape.

Other Top Trending Reports:

 

 


Frequently Asked Questions (FAQ) :
Global Human Vaccines Market was worth of USD 35.42 Billion in 2017
Global Human Vaccines Market is expected to reach USD 83.54 Billion by the end of 2027 with the CAGR of 9.32% during the Forecast Period.
Novartis AG, Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., AstraZeneca plc, Bharat Biotech, Takeda Pharmaceutical Company Ltd, others
Increasing demand for various vaccines in developing countries, rising investment by key players and government initiative in the vaccine development for different diseases are anticipated to drive the growth of Global human vaccines market
North America is set to maintain its Dominance in Global Human Vaccines Market



Interested in this report?

Human Vaccines Market Size, Share, Trends, Demand, And Industry Growth By 2027

report cover

Request for Table of Content

Human Vaccines Market Size, Share & Trends Analysis Report By Type (Combination, Attenuated, Inactivated, Conjugate, Recombinant, Others) By Product (Rotavirus, Hepatitis, Influenza, Typhoid, Rubella, Others) By Distribution Channel (Hospital, Drugstores, Others) Based on Region, And Segment Forecasts, 2021 - 2027

Note: For delivery of sample pages you must have a Domain Specific Email ID, normally your business email address complies. Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSNetc. are not accepted.
Brandessence market research actively tracks, monitors, and analyses key industry trends in real-time via B2B surveys in 60 + countries and territories.

    Pricing


Looking for Regional Reports?